Vaxcyte, Inc. (PCVX) News
Follow Vaxcyte, Inc. (PCVX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Vaxcyte Q3 Loss Smaller Than Estimates; Plans VAX-31 Filing in H1 2028
Vaxcyte reported a Q3 loss smaller than estimates and plans to file VAX-31 in the first half of 2028.
EQUITY | Nov 04, 2026, 10:09 PM UTC
L
Vaxcyte Reports Q3 Net Income Below Zero
Vaxcyte reported Q3 operating expenses of $308.274 million. Net income was below zero, compared with the IBES estimate.
EARNINGS | Nov 04, 2026, 09:12 PM UTC
M
Vaxcyte Reports Q3 2026 Results, Positive VAX-31 Phase 3 Topline Data
Vaxcyte reported third-quarter 2026 financial results and announced positive topline data from the OPUS-1 pivotal Phase 3 trial for VAX-31’s adult indication.
EQUITY | Nov 04, 2026, 09:08 PM UTC
H
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Author Stephen King has criticized President Donald Trump’s new White House press secretary, Katie Zacharia, over her past social media posts promoting vaccine-related claims, questioning the 2020 election results and al
LIVE | Oct 12, 2026, 09:12 AM UTC
H
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh investor interest in vaccine makers, sending several biotechnology and pharmaceutical stocks higher Friday. Moderna, Inc. (NA
LIVE | Oct 09, 2026, 07:11 PM UTC
H
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index surging around 350 points on Tuesday. The Dow traded up 0.69% to 51,622.17 while the NASDAQ jumped 0.79% to 27,694.08. The S&P 500 also rose, gai
LIVE | Oct 06, 2026, 04:04 PM UTC
H
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus (UPDATED)
Editor’s Note: The ETFs tracking benchmark indices and the headline were updated in the story. U.S. stock futures traded higher on Tuesday, with futures tied to the Dow Jones, S&P 500 and Nasdaq 100 pointing to gains aft
LIVE | Oct 06, 2026, 12:28 PM UTC
H
Stock Market Today: S&P 500, Dow Jones Futures Gain as Scott Bessent Doubles Down on Iran Pressure— OPCH, PCVX, STZ in Focus
U.S. stock futures traded higher on Tuesday, with futures tied to the Dow Jones, S&P 500 and Nasdaq 100 pointing to gains after the major averages closed higher on Monday. Iran’s economic crisis escalated as Oil Minister
LIVE | Oct 06, 2026, 09:22 AM UTC
M
Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data
Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7%
EQUITY | Oct 06, 2026, 07:52 AM UTC
M
Vaxcyte Launches $1 Billion Equity and Convertible Notes Offerings
Vaxcyte has commenced underwritten offerings of $500 million in common stock and pre-funded warrants, and $500 million in convertible senior notes due 2032. Both offerings include 30-day over-allotment options.
EQUITY | Oct 05, 2026, 08:32 PM UTC
H
Vaxcyte Stock Soars After Pneumonia Vaccine Meets Late-Stage Trial Goals
Vaxcyte (PCVX) shares jumped over 60% as its experimental pneumococcal vaccine successfully met the primary endpoints in a pivotal late-stage trial for adult use. This success positions the biotech to compete with establ
EQUITY | Oct 05, 2026, 06:37 PM UTC
M
Vaxcyte Stock Surges Over 25% on Promising Pneumonia Vaccine Trial Results
Vaxcyte shares experienced a significant surge of over 25% following the announcement that its experimental pneumonia vaccine, VAX-31, demonstrated efficacy comparable to existing market vaccines in a large-scale final-s
EQUITY | Oct 05, 2026, 04:48 PM UTC
H
Dow Gains 100 Points; ISM Services PMI Falls In September
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.20% to 51,277.22 while the NASDAQ jumped 0.84% to 27,418.49. The S&P 500 also rose, gain
LIVE | Oct 05, 2026, 04:43 PM UTC
M
Vaxcyte shares jump after late-stage vaccine trial results
Vaxcyte stock surged after late-stage results suggested its lead vaccine candidate could steal significant share from Pfizer and Merck in a multi-billion-dollar market.
EARNINGS | Oct 05, 2026, 02:24 PM UTC
M
Vaxcyte VAX-31 Phase 3 Trial Meets All Primary Endpoints
Vaxcyte reported positive topline Phase 3 OPUS-1 results for VAX-31, meeting all prespecified immunogenicity and safety endpoints versus PCV20/PCV21.
EQUITY | Oct 05, 2026, 12:03 PM UTC
H
Vaxcyte Shares Surge on Pneumococcal Vaccine Trial Success
Vaxcyte announced its experimental pneumococcal vaccine achieved its primary endpoints in a late-stage trial for adults aged 50 and older, causing its shares to jump 91% pre-market.
EQUITY | Oct 05, 2026, 10:46 AM UTC
M
Vaxcyte's VAX-31 meets all pivotal Phase 3 adult endpoints
Vaxcyte reported positive topline results from OPUS-1: VAX-31 met all primary immunogenicity, immunobridging and safety endpoints vs PCV20 and/or PCV21 in adults, with noninferiority across all 321 serotype comparisons i
EQUITY | Oct 05, 2026, 10:08 AM UTC
M
Vaxcyte reports positive topline OPUS-1 data
Vaxcyte said it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.
EQUITY | Oct 05, 2026, 10:00 AM UTC
L
Vaxcyte Price Target Cut to $130.00/Share From $133.00 by B of A Securities
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:33 PM UTC
L
Vaxcyte Price Target Maintained With a $110.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 10:25 AM UTC
M
PCVX to release OPUS-1 phase III data for VAX-31 by end-October
Vaxcyte said OPUS-1 phase III data for VAX-31 will target broader pneumococcal coverage and an improved immune response and is due for release by end of October.
EQUITY | Sep 09, 2026, 08:07 PM UTC
L
PCVX VAX-31 phase III data expected by end of October
OPUS-1 phase III data for VAX-31 are expected to be released by end of October. The company says commercial and manufacturing infrastructure is in place, with pediatric and Group A strep programs advancing.
EQUITY | Sep 09, 2026, 07:40 PM UTC
L
PCVX VAX-31 targets dominant pneumococcal market share
PCVX said its VAX-31 aims for dominant market share with broader pneumococcal vaccine coverage. The company expects pivotal phase III data for VAX-31 by October.
EQUITY | Sep 08, 2026, 08:16 PM UTC
L
Vaxcyte names David McAvoy chief legal and compliance officer
Vaxcyte appointed David McAvoy as chief legal officer, chief compliance officer and corporate secretary, while Mikhail Eydelman remains senior vice president and general counsel.
REGULATION | Sep 03, 2026, 08:42 PM UTC
L
Vaxcyte names Chief Medical Officer, Chief Legal Officer; narrows VAX-31 OPUS-1 topline guidance
Vaxcyte appointed a Chief Medical Officer and a Chief Legal Officer, and narrowed guidance for expected VAX-31 OPUS-1 topline data (initial high-level study results).
EQUITY | Sep 03, 2026, 08:12 PM UTC
L
unresolved to participate in upcoming investor conferences
unresolved said it will participate in upcoming investor conferences.
EQUITY | Aug 27, 2026, 08:07 PM UTC
L
PCVX - Vaxcyte to Participate in Upcoming Investor Conferences
PCVX - Vaxcyte to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 08:05 PM UTC
L
PCVX - Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
PCVX - Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:05 PM UTC
L
PCVX Maintain Buy, $116 PT – now is the time to understand VAX-A1 @ GUGG
PCVX Maintain Buy, $116 PT – now is the time to understand VAX-A1 @ GUGG
EQUITY | Jul 14, 2026, 01:11 PM UTC